Tag - Corbus Pharmaceuticals

Why Corbus Pharmaceuticals Holdings, Inc. Stock Rocketed 412% Upwards in 2016

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) thrilled investors with a 412.1% gain last year, according todata from S&P Global Market Intelligence Opens a New Window. . Positive mid-stage clinical trial results for its lead drug, Resunab, lifted the stock and ignited hope for further expansion in the future. Read more >>

Shares Bringing Holiday Cheer For Investors: Corbus Pharmaceuticals Holdings, Inc.

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have climbed in the previous month. During that time period, shares are up 6.88% which has provided some nice profits for investors who may be looking to take advantage of the recent gains. Focusing in on the past five trading days, shares have changed 4.27%. Year-to-date, the stock has performed 418.18%. Read more >>

Two Biotech Stocks Are Just So Hot Right Now (Corbus Pharmaceuticals Holdings, Inc.)

On November 14, 2016 Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced positive topline results from its Phase 2 study evaluating Resunab (“JBT-101”) for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). JBT-101 out-performed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo. Read more >>

Corbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has completed the Phase 2 study evaluating Resunab for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). Corbus expects to report topline data from this study in the fourth quarter of 2016. Read more >>

Hot Biotech Stocks To Watch Right Now: Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Holdings, Inc. (CRBP) a clinical stage drug development company targeting rare, chronic and serious inflammatory and fibrotic diseases, announced that Professor Derek Gilroy, Ph.D. presented data on the effects of Resunab in a model of inflammation in healthy volunteers on September 28, 2016. The presentation was made at the 6th European Workshop on Lipid Mediators at Goethe University in Frankfurt am Main, Germany. Read more >>

Why Corbus Pharmaceuticals Holdings Inc Shares Skyrocketed Today

Corbus Pharmaceuticals (NASDAQ: CRBP) is up 29% at 1:18 p.m. EDT after an analyst at Cantor Fitzgerald initiated coverage of the biotech with a buy rating.
There’s plenty to learn about Corbus Pharmaceuticals. The biotech only has one drug, resunab, but it’s testing the anti-inflammatory drug in multiple indications: cystic fibrosis, systemic sclerosis, dermatomyositis, and lupus. Read more >>